Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | ROS1 | P08922 | 4/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31664180 | 1.00 | EGFR (0.48) | EGFRPTK2ROS1ALKMET | |
| SCHEMBL30659886 | 0.95 | EGFR (0.48) | EGFRPTK2ROS1ALKMET | |
| SCHEMBL26906847 | 0.95 | EGFR (0.48) | EGFRPTK2ROS1ALKMET | |
| SCHEMBL601464 | 0.89 | GLO1 (0.50) | EGFRPTK2ROS1ALKMET | |
| SCHEMBL1707277 | 0.89 | ZAP70 (0.46) | EGFRPTK2ROS1ALKPIK3CG | |
| SCHEMBL9912361 | 0.85 | ROS1 (0.55) | EGFRPTK2ROS1ALKMET | |
| SCHEMBL1708506 | 0.85 | EGFR (0.59) | EGFRPTK2ROS1ALKMET | |
| SCHEMBL1706931 | 0.85 | ROS1 (0.55) | EGFRPTK2ROS1ALKMET | |
| SCHEMBL1707112 | 0.85 | ALK (0.64) | EGFRPTK2ROS1ALKMET | |
| SCHEMBL23932807 | 0.85 | ALK (0.49) | EGFRPTK2ROS1ALKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| WO-2024072178-A1 | COMPOUND FOR TARGETED PROTEIN DEGRADATION, AND USE THEREOF | (주)사이러스테라퓨틱스 | 2024-04-04 | — | — | WO | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2010146133-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146132-A1 | SULFONAMIDES AND SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010142766-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010118986-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010118986-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EGFR 1156/4885PTK2 1782/4885ROS1 1084/4885 |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | EGFR 17/4885PTK2 491/4885ROS1 12/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EGFR 1156/4885PTK2 1782/4885ROS1 1084/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EGFR 1156/4885PTK2 1782/4885ROS1 1084/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EGFR 1156/4885PTK2 1782/4885ROS1 1084/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EGFR 1156/4885PTK2 1782/4885ROS1 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.